Hoatlin Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
(164 intermediate revisions by 6 users not shown)
Line 1: Line 1:
=Welcome to the Hoatlin Lab Wiki in development.=
{{HoatlinLab}}


Our lab is interested in understanding how the [http://www.fanconi.org/ Fanconi anemia] proteins contribute to genomic stability with the goal of developing drugs that will help Fanconi patients and those who are susceptible to developing cancer.
<div style="padding: 15px; width: 710px; border: 5px solid #B3CD4E;">
We work in [http://www.pova.org/ Portland, Oregon] at [http://www.ohsu.edu/ OHSU], in the [http://www.ohsu.edu/biochem/ Department of Biochemistry & Molecular Biology]. Our Departmental web page (not updated frequently) can be viewed [http://www.ohsu.edu/biochem/faculty/faculty.cfm?facultyID=29 here].
<div style="padding: 1px; width: 700px; border: 3px solid #DDDDFF;">


We hope that other Fanconi labs join us at [http://openwetware.org/wiki/Main_Page/ OpenWetWare] because it might stimulate collaborative efforts and facilitate reagent distribution. We also believe that an understanding of the complex and enigmatic Fanconi anemia protein network could benefit from the attention of systems biologists already on OWW.  
<div style="border:1px solid orange;background-color:#FFFACD;padding:1px;">
----
'''Lab News'''
;For news, follow the [http://twitter.com/HoatlinLab Hoatlin lab Twitter]
</div>
<br>
Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility.  The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility.  Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer.  


We work in [[Hoatlin:Portland Oregon| Portland, Oregon]] at [http://www.ohsu.edu/ OHSU], in the [http://www.ohsu.edu/biochem/ Department of Biochemistry & Molecular Biology] and the [http://www.ohsucancer.com/ OHSU Knight Cancer Institute].


==Bio for Maureen Hoatlin==


*[[Hoatlin:Research Interests|Research Interests]]
Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU).  After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers.  She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002.  Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway.  Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds.
*[[Hoatlin:Lab Members|Lab Members]]
*[[Hoatlin:Publications|Publications]]
*[[Hoatlin:Projects|Projects]]
*[[Hoatlin:Collaborations|Collaborations]]
*[[Hoatlin:Reagent Requests|Reagent Requests]]
*[[Hoatlin: View from our Lab|Our View]]
*[[Hoatlin:Courses and Curriculum Development|Courses and Curriculum Development]]
==[[Hoatlin:OHSU Replication, Recombination and Repair (R3) Club|OHSU Replication, Recombination and Repair (R3) Club]]==


[[Image:Hoatlin_lab_logo.png|frame|"Frog Eggs Rule" illustration by Sobeck&Hoatlin]]
Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development.


[[Simple_wiki_editing_examples|wiki edit instructions]]
==Teaching Links==
 
*Our lab's Fanconi Anemia antibodies are available from [http://www.novusbio.com Novus Biologicals] and by Millipore.
 
[http://www.openwetware.org/wiki/Hoatlin:CONJ606/PMCB CONJ606/PMCB]
 
[[Hoatlin:OHSU_Genetic_Mechanisms_Class| Genetic Mechanisms Class (CON662)]]
 
[[Hoatlin: CSF|Med Students Fundamentals]]
 
==Biochemistry Seminar Series==
[http://www.openwetware.org/wiki/Hoatlin:BMB_seminar_series_2017-2018 Biochemistry Seminar Series and Combined Series Working Draft]
 
==Classes of the past==
[[BMCB625|Advanced Topics in Molecular Biology(BMB625)]]
 
[http://openwetware.org/wiki/CANB_610 Advanced Topics in Cancer Biology (CANB 610)]
 
[[Hoatlin:OHSU Replication, Recombination and Repair (R3) Club| OHSU DNA Replication, Recombination and Repair (R3) Club]].
 
==Who is Visiting Us?==
 
'''Who's visiting?'''
 
<html>
<a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Hoatlin_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Hoatlin_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'">
</a>
</html>
[[Image:Hoatlinclustermap.jpg]]
 
==Basic Wiki/OWW Links==
 
*[http://openwetware.org/wiki/Help:Contents Help Overview]
 
*[[OpenWetWare:How_to_join | How to join]]
 
*[[OWW.101:OpenWetWare | Using OpenWetWare]]
 
*[[OWW.101:Guidelines for editing OpenWetWare|Guidelines for editing OpenWetWare]]
 
<wikionly>
<font size=4>'''Recent changes'''</font>{{Special:Recentchanges/Hoatlin}}
</wikionly>

Revision as of 11:56, 8 August 2017

Equipped with his five senses, man explores the universe around him and calls the adventure Science. ~Edwin Powell Hubble, The Nature of Science, 1954

Home        Projects        Team        Papers        Contact Us        Protocols        Collaborations        News        Reagent Requests        secret back door        Hoatlin Lab Twitter       



Lab News

For news, follow the Hoatlin lab Twitter


Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility. The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility. Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer.

We work in Portland, Oregon at OHSU, in the Department of Biochemistry & Molecular Biology and the OHSU Knight Cancer Institute.

Bio for Maureen Hoatlin

Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU). After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers. She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002. Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway. Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds.

Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development.

Teaching Links

  • Our lab's Fanconi Anemia antibodies are available from Novus Biologicals and by Millipore.

CONJ606/PMCB

Genetic Mechanisms Class (CON662)

Med Students Fundamentals

Biochemistry Seminar Series

Biochemistry Seminar Series and Combined Series Working Draft

Classes of the past

Advanced Topics in Molecular Biology(BMB625)

Advanced Topics in Cancer Biology (CANB 610)

OHSU DNA Replication, Recombination and Repair (R3) Club.

Who is Visiting Us?

Who's visiting?

<html> <a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Hoatlin_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Hoatlin_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'"> </a> </html>

Basic Wiki/OWW Links

<wikionly>

Recent changes
List of abbreviations:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes

25 April 2024

     23:55  Flow and Pattern Asymmetries‎‎ 50 changes history −656 [Courtneychau‎ (50×)]
     
23:55 (cur | prev) −14 Courtneychau talk contribs (→‎Mixing on the Microfluidic Scale)
     
23:55 (cur | prev) −43 Courtneychau talk contribs (→‎Reynolds Number (Re))
     
23:55 (cur | prev) −46 Courtneychau talk contribs (→‎Péclet Number (Pe))
     
23:55 (cur | prev) −31 Courtneychau talk contribs (→‎Stokes Flow)
     
23:54 (cur | prev) −151 Courtneychau talk contribs (→‎Stokes Flow)
     
23:50 (cur | prev) +184 Courtneychau talk contribs (→‎References)
     
23:46 (cur | prev) 0 Courtneychau talk contribs (→‎Active Mixing Methods)
     
23:46 (cur | prev) +1 Courtneychau talk contribs (→‎Passive Mixing Methods)
     
23:45 (cur | prev) 0 Courtneychau talk contribs (→‎Chaotic Advection)
     
23:44 (cur | prev) 0 Courtneychau talk contribs (→‎Mixing on the Microfluidic Scale)
     
23:43 (cur | prev) +28 Courtneychau talk contribs (→‎Stokes Flow)
     
23:39 (cur | prev) +1 Courtneychau talk contribs (→‎Stokes Flow) Tag: Manual revert
     
23:38 (cur | prev) −1 Courtneychau talk contribs (→‎Stokes Flow)
     
23:37 (cur | prev) +11 Courtneychau talk contribs
     
23:36 (cur | prev) +15 Courtneychau talk contribs
     
23:33 (cur | prev) 0 Courtneychau talk contribs (→‎References)
     
23:30 (cur | prev) +3 Courtneychau talk contribs (→‎Passive Mixing Methods)
     
23:28 (cur | prev) −426 Courtneychau talk contribs
     
23:16 (cur | prev) +1,656 Courtneychau talk contribs (→‎References)
     
23:14 (cur | prev) 0 Courtneychau talk contribs (→‎Applications of Asymmetric Flow)
     
23:13 (cur | prev) 0 Courtneychau talk contribs (→‎Active Mixing Methods)
     
23:12 (cur | prev) −1 Courtneychau talk contribs (→‎Passive Mixing Methods)
     
23:11 (cur | prev) 0 Courtneychau talk contribs (→‎Microfluidic Mixers)
     
23:10 (cur | prev) 0 Courtneychau talk contribs (→‎Chaotic Advection)
     
23:08 (cur | prev) 0 Courtneychau talk contribs (→‎Mixing on the Microfluidic Scale)
     
23:06 (cur | prev) +6 Courtneychau talk contribs (→‎References)
     
23:04 (cur | prev) −179 Courtneychau talk contribs (→‎Applications of Asymmetric Flow)
     
23:03 (cur | prev) +16 Courtneychau talk contribs (→‎Pneumatic Valves and Mixers)
     
23:02 (cur | prev) +16 Courtneychau talk contribs (→‎Active Mixing Methods)
     
23:02 (cur | prev) −334 Courtneychau talk contribs (→‎Active Mixing Methods)
     
22:56 (cur | prev) −415 Courtneychau talk contribs (→‎Passive Mixing Methods)
     
22:52 (cur | prev) −115 Courtneychau talk contribs (→‎Herringbone Mixer)
     
22:52 (cur | prev) −457 Courtneychau talk contribs (→‎Passive Mixing Methods)
     
22:38 (cur | prev) 0 Courtneychau talk contribs (→‎Microfluidic Mixers)
     
22:35 (cur | prev) −315 Courtneychau talk contribs (→‎Mixing on the Microfluidic Scale)
     
22:14 (cur | prev) 0 Courtneychau talk contribs (→‎Stokes Flow)
     
22:12 (cur | prev) 0 Courtneychau talk contribs (→‎Péclet Number (Pe))
     
22:11 (cur | prev) +6 Courtneychau talk contribs (→‎Reynolds Number (Re))
     
22:10 (cur | prev) +2 Courtneychau talk contribs (→‎Diffusion and Advection)
     
22:07 (cur | prev) +2 Courtneychau talk contribs (→‎Asymmetries in Microfluidics)
     
22:05 (cur | prev) +2 Courtneychau talk contribs (→‎Asymmetries in Microfluidics)
     
22:04 (cur | prev) +4 Courtneychau talk contribs (→‎Fundamentals of Mixing)
     
22:02 (cur | prev) +471 Courtneychau talk contribs (→‎Asymmetries in Microfluidics)
     
21:52 (cur | prev) +78 Courtneychau talk contribs (→‎Asymmetries in Microfluidics)
     
21:50 (cur | prev) +6 Courtneychau talk contribs (→‎Asymmetries in Microfluidics)
     
21:44 (cur | prev) −1 Courtneychau talk contribs (→‎Twists and Bends)
     
21:39 (cur | prev) 0 Courtneychau talk contribs (→‎Stokes Flow)
     
21:38 (cur | prev) +450 Courtneychau talk contribs
     
20:54 (cur | prev) −1,079 Courtneychau talk contribs
     
20:38 (cur | prev) −6 Courtneychau talk contribs (→‎Herringbone Mixer)

</wikionly>